Biomechanical thrombosis: the dark side of force and dawn of mechanomedicine

Yunfeng Chen, Lining Arnold Ju

ABSTRACT
Arterial thrombosis is in part contributed by excessive platelet aggregation, which can lead to blood clotting and subsequent heart attack and stroke. Platelets are sensitive to the haemodynamic environment. Rapid haemodynamics and disturbed blood flow, which occur in vessels with growing thrombi and atherosclerotic plaques or is caused by medical device implantation and intervention, promotes platelet aggregation and thrombus formation. In such situations, conventional antiplatelet drugs often have suboptimal efficacy and a serious side effect of excessive bleeding. Investigating the mechanisms of platelet biomechanical activation provides insights distinct from the classic views of agonist-stimulated platelet thrombus formation. In this work, we review the recent discoveries underlying haemodynamic force-reinforced platelet binding and mechanosensing primarily mediated by three platelet receptors: glycoprotein Ib (GPIb), glycoprotein Ib/IIa (GPIib/IIa) and glycoprotein VI (GPVI), and their implications for development of antithrombotic ‘mechano-medicine’.

INTRODUCTION
Thrombotic diseases, which include the acute coronary syndromes, ischaemic stroke and peripheral vascular disease, remain the leading causes of death and disability worldwide. Platelets play a central role in the pathogenesis of arterial thrombosis. However, despite intensive investigations over the last 40 years into the discovery and development of antiplatelet therapies, the impact of these therapies on the mortality rate remains disappointingly low: <1 in 6 patients taking antiplatelet therapies avoided a fatal thrombotic event. This situation is likely to worsen in the next few decades due to the rapidly growing incidence of obesity, diabetes and metabolic syndrome, which all enhance the resistance of arterial thrombosis to conventional antiplatelet drugs.

The development of more effective anti-thrombotic approaches requires a better understanding of the molecular events underlying platelet hyperactivity and excessive thrombus growth. To date, most of the Food and Drug Administration (FDA) approved anti-thrombotic agents target agonist pathways of platelet activation, including the purinergic P2Y12 receptor antagonists (clopidogrel, prasugrel, ticagrelor), inhibitors of thromboxane A2 (TxA2) generation (aspirin, triflusal) or protease-activated receptor 1 (PAR1) antagonists (vorapaxar). Increasing the dose of these agents, especially aspirin and clopidogrel, has been employed to dampen the platelet thrombotic functions. However, this also increases the risk of excessive bleeding. It has long been recognized that arterial thrombosis is regulated by biomechanical factors, particularly pathological shear stress and flow disturbance associated with vessel stenosis induced by atherosclerotic plaques or medical device implants. These variations in blood haemodynamics can be sensed by platelets, upregulating platelet adhesive functions and inducing platelet activation via a process called ‘mechanosensing’. Recent technology advancements in microfluidics, molecular imaging and live-cell dynamic force spectroscopy enabled the investigation of platelet mechanosensing at single-cellular and single-molecular levels. These studies looked into how platelets sense and react to the extracellular haemodynamic forces, and defined the mechanosensing functions of receptors GPIb, GPIb/IIa and possibly GPVI, in mediating shear-dependent platelet adhesion, spreading and aggregation. These insights provided new targets for the next-generation antithrombotic strategies.

Biomechanical versus biochemical activation in platelet adhesion and aggregation
Thrombosis requires platelet adhesion, but also heavily relies on platelet aggregation to form occlusive thrombi. Platelet adhesion and aggregation are both complex processes that involve the binding between multiple receptor–ligand pairs. In veins where shear rates are low (300–800 s^{-1}), initial platelet adhesion is mainly mediated by GPVI interaction with collagen and GPIib/IIa with fibrinogen in subendothelium (figure 1). The subsequent platelet aggregation is primarily mediated by the GPIib/IIa binding to divalent or
Figure 1  Illustration of VWF mechanoactivation (inset) and the step-by-step process of GPIb-mediated platelet mechanosensing. VWF is activated by shear flow in two steps: it is first globally elongated from a globular to an extended conformation, followed by the relief of its A1 domain autoinhibition that enables binding to platelet GPIβx. Once VWF is bound to a platelet, force from the shear flow transmits from VWF to GPIβx and triggers a series of GPIβx conformational changes and allosteric effects. These events would result in the reinforcement of VWF–GPIβ interaction as well as the initiation of a mechanosignaling pathway that eventually leads to intracellular calcium release and GPIIb/IIIa activation. Note: platelet GPVI and its interaction with collagen are also depicted in this graph. Agents and drugs that have the potential to inhibit arterial thrombosis by targeting GPIb-mediated or GPVI-mediated platelet binding and mechanosensing, and their respective targets, are indicated, corresponding to table 1.

multivalent ligands for crosslinking. These include von Willebrand factor (VWF), which adopts a structure of a colloid concatemer,14–16 and fibrinogen, which has a total of six motifs to interact with GPIIb/IIIa.17–19 In addition, fibronectins can attach to two ends of a fibrinogen molecule and crosslink platelet GPIIb/IIIa as well.20–22 In arteries and arterioles where shear rate is relatively high (>800 s⁻¹), both GPIb and GPIIb/IIIa serve as the primary mediators of platelet adhesion23 24 and aggregation.5 25 In particular, at pathologically high shear rates (>5000 s⁻¹) that occur in arteries with severe stenosis, the GPIb–VWF interaction alone can achieve large-scale platelet aggregation independent of integrin and platelet activation.26

Platelet adhesion and aggregation are heavily dependent on platelet activation, mainly due to the fact that platelet activation primes GPIIb/IIIa to achieve stronger binding capacity.13 23 Additionally, platelet activation also results in platelet spreading and granule release to allow ligand deposition as well as surface expression of extra receptors for binding.11 27–29 Platelets can be activated by soluble agonists via G protein-coupled receptor (GPCR) signaling pathways. For instance, ADP (by binding to P₂Y₁ and P₂Y₁₂),30 31 thromboxane A2 (by binding to thromboxane A2 receptor)32 and thrombin (by binding to PAR1 and PAR4)33 can induce GPIIb/IIIa inside-out activation at various levels to trigger cytoskeletal remodelling, granule release, degranulation and cell death,1 34 35 while the inhibition of these interactions or their subsequent signaling pathways has been employed to develop anti-thrombotic drugs like clopidogrel,36 aspirin,37 warfarin38 and heparin.39 In parallel, platelets can be biomechanically activated via binding to its extracellular ligands under shear.1 In this process, force pulling on a platelet receptor triggers ‘mechanosignals’ across the membrane and results in intracellular signal transduction.6 Platelet GPIb and GPIIb/IIIa together form an important mechanosensing axis.40 GPIb initiates platelet mechanosignaling by binding to immobilised VWF under force, which is followed by the mechanosignaling of GPIIb/IIIa while binding to its own ligands, eventually allowing rapid...
shear-dependent thrombus formation. Importantly, the intensity and timing of GPIb mechanosignaling is quantitatively correlated with the level of subsequent GPIb/IIa activation in both affinity and avidity, which highlights the role of GPIb as a mechanosensor in shear-dependent platelet thrombus formation.

The role of VWF–GPIb axis in platelet binding and mechanosensing

VWF contains binding sites for both platelet GPIb and GPIb/IIa, respectively, in its A1 and C4 domains. The VWF molecule itself is mechanosensitive, which undergoes conformational activation under shear force. The inactive form of VWF in plasma adopts a globular, irregularly coiled shape, with its functional epitopes buried. Adjacent N-terminal A2 domain, which prevents the accessibility of VWF to GPIb. Under high-shear laminar flow or high-shear gradient disturbed flow, VWF is mechanically extended by shear force to expose its platelet-binding epitopes. Further exertion of force on the extended VWF unmasks its A1 domain and relieves the autoinhibition of its GPIb-binding site, thereby allowing platelet GPIb binding (figure 1). Besides, shear can facilitate the self-association of VWF into fibres, which further enhances platelet adhesion and activation.

The VWF A1 domain autoinhibition was suggested to be controlled by the C1669–C1670 disulfide bond plug in the A2 domain. Three different redox forms of this disulfide plug were discovered to exist in circulating human VWF: reduced, glutathionylated and oxidized. The oxidized form has high affinity for platelet GPIb, whereas the reduced and glutathionylated forms have low affinity. Clinically, most of heart failure patients who have received extracorporeal membrane oxygenation (ECMO) support have markedly more oxidized VWF in the circulation, which seems to result from the dysregulated blood flow associated with the device but not the disease or therapy variations. This result explains the thrombotic complications associated with ECMO device, and suggests that reducing this disulfide plug might provide protection to patients against thrombosis.

The VWF–GPIb interaction features fast bond association and dissociation, which plays a primary role in platelet recruitment from rapid blood circulation. A counterintuitive phenomenon was discovered in this interaction: increasing the shear rate would enhance, rather than reduce, platelet adhesion onto a VWF-coated surface. Using single-cell force spectroscopies, this phenomenon was explained by a ‘catch bond’ behaviour and a force-induced unfolding of the GPIb leucine rich repeat (LRR) domain, in both of which mechanical force reinforces VWF–GPIb bond strength (figure 1). Taken together, the mechanosensitivity of VWF and the force reinforcement of VWF–GPIb interaction work cooperatively to allow platelets to resist high-shear forces in the arteries while being recruited to the vascular injury site. However, they also promote thrombus development under pathological shear conditions as shear rate increases to 5000 s⁻¹, the VWF–GPIb interaction starts to mediate large platelet aggregate formation (>100 μm²), and this effect becomes more pronounced as the shear rate increases to 10000 s⁻¹ and above.

VWF–GPIb interaction not only mediates platelet binding but also triggers the outside-in mechanosignals of platelets independent of other receptors, leading to intraplatelet calcium flux and GPIb/IIa activation. Inhibition of the GPIb-activated Ca²⁺ signal prevents platelet firm adhesion, suggesting that Ca²⁺ is an obligatory signaling molecule on the pathway to GPIb/IIa activation. Although how the transmission of the mechanical signal across the membrane and its transduction into cytoplasmic chemical signals are fulfilled remains elusive, a juxtamembrane mechanosensitive domain (MSD) in the GPIbα subunit was found to correlate with intraplatelet Ca²⁺ triggering (figure 1): force-induced MSD unfolding is well correlated with an α-type Ca²⁺ signal and the subsequent GPIb/IIa intermediate activation, whereas failing to unfold MSD will most likely result in β-type or null-type Ca²⁺ signals and limit GPIb/IIa activation. Intracellularly, a scaffold protein that binds to GPIb cytoplasmic tail, 14-3-3ζ, was also found to play a pivotal role in GPIb mechanosignaling (figure 1), as the inhibition of 14-3-3ζ–GPIb association strongly inhibited GPIb-activated Ca²⁺ flux and subsequent GPIb/IIa activation. Filamin A, another cytoplasmic protein that links GPIb with the cytoskeleton, was also speculated to participate in GPIb mechanosignaling (figure 1). At the downstream of this signal transduction pathway, the phosphorylation of kinases (including Akt and focal adhesion kinase (FAK)) is required, which involves the Src family kinases as well as the activation of several signaling pathways including the phosphoinositide 3-kinase (PI3K)-Akt and cGMP-dependent protein kinase pathway, mitogen-activated protein kinase (ERK1/2 and p38) pathway and LIM kinase 1 pathway.

Targeting VWF–GPIb axis as a novel antithrombotic strategy

Many works have explored the potential of inhibiting VWF–GPIb interaction to reduce arterial thrombosis. For instance, Chen et al discovered a ‘hot spot’ residue R1326 on murine VWF-A. Mutating this residue to histidine weakens both the association and endurance of VWF–GPIb binding, thereby diminishing thrombus formation in arterioles in a laser-injury thrombosis model. The autoinhibitory effect of the N-terminal sequence Q1238-E1260 of VWF-A1 on its own binding to platelet GPIb inspires another potential antithrombotic approach: the soluble polypeptide Lp of the same sequence was shown to inhibit platelet binding to VWF under shear. A humanized anti-VWF-A1 blocking nanobody named ALX-0081 (caplacizumab) inhibited acute thrombosis without compromising haemostasis in baboons and induced the reperfusion of a thrombus-occluded cerebral artery without provoking cerebral...
bleeding in guinea pigs. Besides, an inhibitory monoclonal antibody against VWF-A1, NMCA, a recombinant mimetics of human GPIbαz, GPG-290, and an anti-VWF aptamer, ARC1779, were also found to inhibit thrombosis (table 1; figure 1). Similarly, the inhibition of GPIb binding by monoclonal antibodies H6B4 and p0p/B, or by chemicals purified from snake venom like agkistin and anfibatide, were found to reduce platelet aggregation and thrombus formation under arterial shear conditions (table 1; figure 1). The anti-GPIb blockade has displayed a strong protective effect in the mouse stroke models without inducing significant intracranial bleeding. Notably, unpublished phase IIa human clinical trials have shown the promise of anfibatide as a novel antiplatelet agent without significantly affecting haemostasis in patients with non-ST segment elevation myocardial infarction (MI). Additionally, anfibatide was also shown as a promising candidate to treat ischemic stroke and spontaneous or bacterial shigatoxin-induced acquired thrombotic thrombocytopenic purpura (TTP) in experimental animal models.

Nonetheless, due to the indispensable role of VWF–GPIb interaction in initiating platelet haemostatic functions, inhibiting this axis can easily trigger a strong side effect of excessive bleeding. Historically, this has caused the failure of several clinical trials. For instance, although a phase II trial demonstrated that ARC1779 reduced cerebral thromboembolism after carotid endarterectomy, two-thirds of patients receiving ARC1779 experienced haemorrhagic complications. As another example, caplacizumab was trialled in combination with aspirin, clopidogrel and heparin in high-risk patients with acute MI undergoing percutaneous coronary intervention (PCI). However, its development was discontinued in 2011 because of a severe bleeding profile. Instead, it received FDA approval following phase III HERCULES trials for the treatment of acute episode of acquired TTP in adult patients in combination with plasma exchange and immunosuppressive therapy. We argue that similar outcome may hold true for other drug candidates that generally inhibit VWF–GPIb interaction, which deserve careful consideration and further investigation.

On a separate note, considering the distinct haemodynamic conditions associated with arterial thrombosis and haemostasis, a potential strategy to selectively inhibit arterial thrombosis without compromising haemostasis is to target the biomechanical activation of VWF and/or the biomechanical reinforcement of VWF–GPIb interaction. For instance, inhibiting the LRR domain unfolding of GPIbαz may serve to suppress VWF–GPIb interaction under high forces, thereby hampering thrombosis in stenosed arteries where shear rate is pathologically high. As another example, shear force unfolds the A2 domain of ultra-large VWF to allow its cleavage by ADAMTS13 into normal sizes. It was found that under pathologically high-shear flow, shear force becomes sufficiently large to trigger cleavage of normal-sized VWF by ADAMTS13 in a growing thrombus, thereby inhibiting thrombosis.

This makes recombinant ADAMTS13 (BAX 930) a promising antithrombotic agent (table 1; figure 1): in preclinical tests, infusing recombinant ADAMTS13 before reperfusion significantly reduced the infarct volume and other stroke effects. Moreover, the mechanoredox regulation of VWF reactivity suggests that using antioxidative agents or more specific disulfide isomerases to reverse plasma VWF from oxidized to its reduced form can reduce platelet binding and thereby suppress thrombosis.

Since GPIb mechanosignaling leads to GPIIib/IIIa activation, the GPIIib signaling pathway serves as another target to inhibit thrombosis. However, blocking housekeeping cytoplasmic adaptors and signaling kinases would most likely affects physiological functions of other cell types. Considering this, targeting certain steps of the GPIb mechanosignaling process seems more promising due to higher specificity. Previous works have identified that a small peptide, MPαC, which inhibits the association of 14-3-3ζ with GPIb, suppresses mouse arterial thrombosis with minor consequences of bleeding (table 1; figure 1). Inhibiting the unfolding of MSD should also suppress the mechanosignaling of GPIb. The current development of bispecific antibody technology provides a possible approach to achieve this: by making a bispecific antibody with two antigen binding fragments respectively targeting the two ends of MSD, it can potentially constrain MSD in its folded conformation even under force pulling.

The role of GPIIib/IIIa in platelet binding and mechanosensing

A good amount of works have substantially characterized GPIIib/IIIa as a platelet receptor in structure, binding activity and signaling: GPIIib/IIIa regulates its ligand-binding affinity with conformational changes. Inactive GPIIib/IIIa adopts a bent conformation (B) with closed headpiece (C) (or called hybrid domain swung-in); its ligand binding site is inactive and barely binds any ligand. On activation, the GPIIib/IIIa extends its ectodomain to achieve an extended-closed (EC) conformation, followed by headpiece opening to reach extended-open (EO) form (figure 2A). The EO conformation of GPIIib/IIIa is extensively correlated with active ligand binding, whereas the EC conformation was recently found to be associated with an intermediate affinity state.

GPIIib/IIIa plays critical roles in platelet adhesion, activation and aggregation, which altogether define it as the primary mediator of both thrombosis and haemostasis. As first observed in mouse stenosed blood vessels and in varied arterial injury models, GPIIib/IIIa can mediate platelet aggregation in a biomechanical pathway, where the platelets mainly remain discoid. In the biomechanical platelet aggregation, the interaction between GPIIb and VWF initiates platelet mechanosensing and results in the EC conformation, intermediate affinity activation of GPIIib/IIIa. Once upregulated to this intermediate state, GPIIib/IIIa starts to receive mechanosignals to undergo outside-in signaling, which leads to its own activation to the high affinity, EO state (figure 2A).
Table 1  Novel antiplatelet agents targeting GPIb, GPIb/IIIa and GPVI mechanosensing axes

<table>
<thead>
<tr>
<th>Axis</th>
<th>Target</th>
<th>Agent</th>
<th>Description</th>
<th>Antithrombotic effect</th>
<th>Phase of development</th>
<th>Clinical trials gov identifier</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>14-3-3ζ</td>
<td>MPαC</td>
<td>Designed based on the 14-3-3ζ-binding sequence in GPIbα. Blocks 14-3-3ζ binding to GPIbα.</td>
<td>Weakens GPIbα-VWF interaction and inhibits GPIbα mechanosignalling.</td>
<td>Preclinical</td>
<td></td>
<td>92, 93</td>
</tr>
<tr>
<td>VWF</td>
<td>BAX 930</td>
<td>Recombinant ADAMTS13; cleaves VWF at A2 domain to weaken its activity.</td>
<td></td>
<td>Inhibits arterial thrombosis.</td>
<td>III</td>
<td>NCT03393975</td>
<td>88, 89</td>
</tr>
<tr>
<td>VWF</td>
<td>NMC4</td>
<td>A monoclonal antibody against VWF-A1.</td>
<td></td>
<td>Inhibits arterial thrombosis.</td>
<td>Preclinical</td>
<td></td>
<td>73</td>
</tr>
<tr>
<td>VWF</td>
<td>Caplacizumab</td>
<td>A nanobody against VWF-A1.</td>
<td></td>
<td>Showed inhibitory effects on thrombosis in primate models without causing adverse side effects.</td>
<td>FDA approved</td>
<td></td>
<td>71, 72</td>
</tr>
<tr>
<td>VWF</td>
<td>ARC1779</td>
<td>An anti-VWF aptamer.</td>
<td></td>
<td>Showed encouraging results in inhibiting thrombosis.</td>
<td>II (terminated)</td>
<td>NCT00742612</td>
<td>75, 85</td>
</tr>
<tr>
<td>GPIbα</td>
<td>p0p/B</td>
<td>An antibody against GPIbα.</td>
<td></td>
<td>Dramatically reduces infarct volumes in cerebral ischaemia model.</td>
<td>Preclinical</td>
<td></td>
<td>77</td>
</tr>
<tr>
<td>GPIbα</td>
<td>H6B4</td>
<td>An antibody against GPIbα.</td>
<td></td>
<td>Inhibits high-shear arterial thrombosis in baboons without causing adverse side effects.</td>
<td>Preclinical</td>
<td></td>
<td>76</td>
</tr>
<tr>
<td>GPIbα</td>
<td>GPG-290</td>
<td>A recombinant human GPIbα chimeric protein which blocks GPIbα binding to VWF.</td>
<td></td>
<td>Inhibits coronary artery thrombosis in a canine model.</td>
<td>Preclinical</td>
<td></td>
<td>74</td>
</tr>
<tr>
<td>GPIbα</td>
<td>agkistin</td>
<td>Blocks GPIbα binding to VWF.</td>
<td></td>
<td>Reduces thrombus formation under arterial shear conditions.</td>
<td>Preclinical</td>
<td></td>
<td>78</td>
</tr>
<tr>
<td>GPIbα</td>
<td>Anfibatide</td>
<td>Inhibits both VWF and α-thrombin binding to GPIbα.</td>
<td></td>
<td>In experimental models, inhibits platelet adhesion, aggregation and thrombus formation without increasing bleeding time.</td>
<td></td>
<td>I, II</td>
<td>NCT01585259</td>
</tr>
<tr>
<td>Axis</td>
<td>Target</td>
<td>Agent</td>
<td>Description</td>
<td>Antithrombotic effect</td>
<td>Phase of development</td>
<td>Clinical trials gov identifier</td>
<td>References</td>
</tr>
<tr>
<td>------</td>
<td>--------</td>
<td>-----------</td>
<td>-------------------------------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------------</td>
<td>----------------------</td>
<td>--------------------------------</td>
<td>------------</td>
</tr>
<tr>
<td>GPIIb/IIIa</td>
<td>PI3Kβ</td>
<td>AZD6482</td>
<td>Inhibits PI3Kβ downstream GPIIb/IIIa mechanosignaling and shear-induced platelet activation.</td>
<td>Inhibits thrombus formation in vivo in preclinical models with minimal effects on bleeding.</td>
<td>I</td>
<td>NCT00853450</td>
<td>136</td>
</tr>
<tr>
<td></td>
<td>Gα13</td>
<td>mP6</td>
<td>A myristoylated peptide (Myr-FEERA) that inhibits association of Gα13 with integrin β3 cytoplasmic tail and suppresses the early phase of GPIIb/IIIa outside-in signaling.</td>
<td>Inhibits platelet spreading and thrombus formation in preclinical models with no effects on bleeding time.</td>
<td>Preclinical</td>
<td></td>
<td>104</td>
</tr>
<tr>
<td>PDI</td>
<td></td>
<td>Isoquercetin</td>
<td>Inhibits PDI activity in plasma and decreases platelet-dependent thrombin generation; also reduces levels of coagulation markers at higher doses.</td>
<td>Inhibits platelet thrombus formation and fibrin formation in preclinical models. Partial inhibition does not cause serious bleeding.</td>
<td>II–III</td>
<td>NCT02195232</td>
<td>141</td>
</tr>
<tr>
<td>Active GPIIb/IIIa</td>
<td></td>
<td>scFv SCE5</td>
<td>Single-chain antibody that specifically inhibits the active conformation of GPIIb/IIIa; can also be used to deliver clot-directed thrombolytic, antiplatelet and anticoagulant agents.</td>
<td>Inhibits platelet aggregation and thrombus formation in preclinical models without major increase in bleeding time.</td>
<td>Preclinical</td>
<td></td>
<td>145</td>
</tr>
<tr>
<td>GPIIb/IIIa</td>
<td></td>
<td>RUC-4</td>
<td>A small molecule that binds to the metal ion-binding site on the GPIIIa without causing major conformational changes; specific to GPIIb/IIIa (αIIbβ3) over αVβ3 integrins.</td>
<td>Inhibits platelet aggregation and thrombus formation in preclinical models; effects on bleeding not yet evaluated.</td>
<td>I</td>
<td>NCT03844191</td>
<td>150</td>
</tr>
<tr>
<td>GPIIb/IIIa</td>
<td>PSI A1, PSI B1, PSI C1, PSI E1</td>
<td>Antibodies against GPIIIa PSI domain, inhibiting its thiol isomerase function.</td>
<td>Inhibits platelet aggregation and thrombus formation in preclinical models.</td>
<td>Preclinical</td>
<td></td>
<td>128</td>
<td></td>
</tr>
<tr>
<td>GPVI</td>
<td></td>
<td>9O12</td>
<td>A monoclonal antibody Fab that blocks the collagen/fibrin-binding site of GPVI with high affinity. The recombinant scFv version is also available.</td>
<td>Inhibits thrombosis and appears to maintain haemostasis in preclinical models.</td>
<td>Preclinical</td>
<td></td>
<td>163</td>
</tr>
<tr>
<td>Collagen</td>
<td></td>
<td>Revacept</td>
<td>Dimeric GPVI-Fc that blocks vascular collagen at sites of plaque or vascular erosion and collagen-induced platelet activation</td>
<td>Inhibits platelet thrombus formation at sites of vascular injury in preclinical models; no effect on bleeding time.</td>
<td>I, II</td>
<td>NCT01645306</td>
<td>165</td>
</tr>
<tr>
<td>GPVI</td>
<td></td>
<td>Losartan (DuP-753)</td>
<td>An angiotensin II (Ang II) type I receptor (AT1R) antagonist that has been reported to exert an anti-platelet activity besides its antihypertensive effect.</td>
<td>Inhibits platelet adhesion to collagen and subsequent collagen induced platelet activation and aggregation via GPVI.</td>
<td>IV</td>
<td>NCT00805311</td>
<td>169</td>
</tr>
</tbody>
</table>

PDI, protein disulfide isomerase; scFv, single-chain variable fragment.
as well as platelet spreading, extracellular Ca$^{2+}$ influx and granule secretion. Remarkably, the above process does not require the external supplement of soluble agonists. Therefore, the activation of GPIIb/IIIa via this pathway was named ‘mechanical affinity maturation’. Likely serving as a self-inhibitory mechanism to avoid overly activation of platelets, only the intermediate state, but not inactive state GPIIb/IIIa can undergo outside-in mechanosignaling. Importantly, the biomechanically driven activation (via sequential GPIb and GPIIb/IIIa mechanosignaling) and agonist-stimulated activation (via stimulation of soluble agonists) of GPIIb/IIIa are essentially distinctive and probably via differential signaling pathways. Mechanoredox coupling has been unravelled as a new mechanism by which GPIIb/IIIa biomechanically regulates platelet thrombosis. Thiol isomerases, including protein disulfide isomerase (PDI), endoplasmic reticulum 5 (ERp5), and ERp57 are enzymes which regulate the function of platelets by reducing or oxidising disulfide bonds of their cell surface proteins, such as GPIIb/IIIa. Importantly, the regulation of these thiol isomerases can either strengthen or weaken GPIIb/IIIa binding. For example, the PSI domain of GPIIb/IIIa contains an endogenous thiol isomerase function, the inhibition of which suppressed platelet aggregation. On the other hand, another thiol isomerase ERp5 is secreted by activated platelets and binds to GPIIIa.
Via reducing the βI domain C177–C184 disulfide bond nearby the fibrinogen binding pocket of GPIIb/IIIa, ERp5 results in the premature release of fibrinogen. Importantly, Passam et al identified this process to be force sensitive: RGD-ligand binding to the integrin and shear force can facilitate ERp5 to reduce the disulfide bond, thereby accelerating fibrinogen dissociation (figure 2B). This intriguing finding provides a new concept on how platelets harness force to balance haemostatic versus thrombotic functions from a redox perspective.

**Targeting GPIIb/IIIa as a novel antithrombotic strategy**

Just like GPIb, antagonists that directly block GPIIb/IIIa extracellular binding have been developed for antithrombotic use. Among them, abciximab, eptifibatide and tirofiban are approved by FDA for acute cardiac ischaemic events. However, these antagonists would compromise haemostasis and induce profound thrombocytopenia with mechanisms incompletely understood. Clinicians have to heavily rely on the fine tuning of dosage to prevent these side effects from being life-threatening, which often fails. As a result, these GPIIb/IIIa inhibitors seem to be restricted to particular high-risk subgroups, such as MI patients undergoing PCI without pretreatment with a P2Y₁₂ antagonist. In the case of acute/moderate ischaemic stroke, their use is not recommended until multicentre analyses of endovascular stroke therapy necessitating adjunctive GPIIb/IIIa inhibitors are conducted.

For the last decades, breakthroughs from basic research suggest new antithrombotic therapeutic targets underlying the early phases of GPIIb/IIIa intracellular signaling pathway. For instance, selectively targeting GPIIb/IIIa downstream signaling molecules PI3Kβ and Gα₁₅ was shown to inhibit arterial thrombosis without affecting haemostasis under certain doses (table 1; figure 2A). The PI3Kβ inhibitor AZD6482, which suppresses GPIIb/IIIa mechanosignaling in particular, has completed preclinical and phase I clinical trials, and was demonstrated in multiple species including mice, rats, rabbits, dogs and humans for its good tolerance without prolonging skin bleeding time, even when administered at high doses. AZD6482 also demonstrated high efficiency in reducing the disturbed flow enhanced thrombotic response in a diabetic mouse model, which displayed resistance to co-administered aspirin and clopidogrel, suggesting that targeting platelet mechanosensing pathways provides a potentially more effective antithrombotic approach for patients with diabetes. On the other hand, inhibiting the interaction between GPIIb/IIIa and Gα₁₅ with a myristoylated peptide ExE peptide motif (mPExE) selectively inhibits GPIIb/IIIa mediated platelet spreading but not agonist induced inside-out signaling or fibrinogen ligation (figure 2A). This peptide was shown to suppress occlusive arterial thrombosis without affecting bleeding. To explain this, our single-platelet analyses suggested that Gα₁₅ binding is needed for the active EO state activation of GPIIb/IIIa, but not for the intermediate EC state activation (unpublished data). As such, preventing GPIIb/IIIa from the EC–EO transition might be a promising strategy to differentiate occlusive thrombosis from haemostasis.

The regulation of thiol isomerases was also suggested for antithrombotic application. For instance, inhibiting the thiol isomerase function of GPIIb/IIIa PSI domain by anti-PSI antibodies was demonstrated to inhibit murine thrombus formation without significantly affecting bleeding (figure 2B; table 1). Furthermore, inhibitors of PDI have been identified by high-throughput screening of 350,000 compounds. Isoquercetin, a first-generation flavonoid anti-PDI drug derived from this screening, demonstrated good efficacy for reducing venous thrombosis in cancer patients in a phase II clinical trial (figure 2B; table 1). These exciting results corroborate the rationale of targeting disulfide redox states of GPIIb/IIIa via thiol isomerase inhibitors. Importantly, patients with diabetes and metabolic syndrome have increased thiol isomerase activity in their blood, which raises the possibility of applying these inhibitors to these patients in the future.

Another promising antithrombotic strategy is to inhibit, but not eliminate, the ligand-binding capacity of GPIIb/IIIa. Catch bond mechanism was demonstrated to reinforce the ligand binding of activated GPIIb/IIIa; in particular, compared with the EC intermediate state, the lifetime of EO GPIIb/IIIa is not only globally prolonged under all forces but also stretches its ‘catch’ regime with a wider force range (figure 2C). Such conformation-specific binding attributes of GPIIb/IIIa leads to steady development of thrombi even under pathologically shear rates in stenosed arteries. Taking advantage of this, a potential antithrombotic approach could be to downregulate the catch bond behaviour of activated GPIIb/IIIa at large forces. As a proof-of-concept, we demonstrated that a variant (R77H) in another integrin, α₇β₃, suppresses the integrin catch bond at 5–12 pN, but causes no effect to the bond lifetime at lower forces (<5 pN). Noting that R77 is located in the β-propeller domain distal to the ligand-binding site, this discovery highlights an allosteric effect in integrin binding regulation by integrin α₇-subunit, which may also be applied to platelet GPIIb/IIIa. The conformation-specific targeting of GPIIb/IIIa represents another promising approach to partially inhibit GPIIb/IIIa. The selective targeting of the active EO conformation of GPIIb/IIIa should inhibit the propagation and stabilisation of thrombi, but not the formation of an initial haemostatic platelet plug on vascular injury—a process that relies on GPIIb/IIIa being in the low-activating BC/EC state.

Indeed, this concept has been proven in principle where a single-chain variable fragment (scFv) SCE5 directed against the active conformation of GPIIb/IIIa markedly inhibited thrombosis on both human and mouse platelets (figure 2A), but did not prolong bleeding time in mouse models. Moreover, conformation-specific scFvs have been used to deliver targeted antithrombotic agents such as the.
ADP-hydrolysing enzyme CD39, the potent factor Xa inhibitor tick anticoagulant peptide, and the fibrinolytic agent urokinase to the selective sites of developing clots, which all displayed potent antithrombotic effects in preclinical models without affecting haemostasis.

One caveat of GPIb/IIIa inhibitors is that most of them can potentially induce the receptor to undergo a major conformational change that either exposes neoepitopes for platelet clearance or trigger high-affinity state when the drug dissociates from the receptor, facilitating instead of inhibiting its binding to ligand. This could cause the paradoxical increase in mortality on treatment for MI patients. As an alternative, a small-molecule GPIb/IIIa antagonist, known as RUC-4, binds to the metal ion-binding site on the GPIb/IIIa. It inhibits ligand binding but does not induce GPIb/IIIa conformational change or activation (figure 2A). Furthermore, in preclinical studies, RUC-4 showed potent antithrombotic efficacy (table 1). An interesting aspect of RUC-4 is its suitability for intramuscular injection, which raises the prospect of administration in prehospital emergency settings. However, the bleeding risk profile of this agent remains to be evaluated.

**GPVI: a potential mechanosensor and antithrombotic target**

Aside from GPIb and GPIb/IIIa, many other receptors on platelet surface may also mediate platelet mechanosensing. One topical candidate is GPVI, which is exclusively expressed on platelets and megakaryocytes. It is associated with the Fc receptor γ-chain, which contains an immunoreceptor tyrosine-based activation motif (ITAM). Its engagement with ligands, such as collagen, leads to ITAM-dependent signaling and potent platelet activation. GPVI plays an important role in haemostasis and thrombosis, not only via its own binding to collagen but also through the triggering of GPIb/IIIa and integrin αβ_3 activation. In this context, GPVI was suggested to play a mechanosensing role. However, direct evidence and the detailed mechanosensing mechanism are yet to be revealed. Recently, fibrin was identified as a new GPVI ligand. GPVI-fibrin interaction seems to stabilize thrombus formation under both low-shear and high-shear conditions. Moreover, GPVI was suggested to co-associate with GPIbα to coordinate thrombotic output across these haemodynamic conditions. Intriguingly, patients and mice with GPVI deficiency only display a mild bleeding diathesis, whereas mice lacking GPVI are protected against arterial thrombosis and subsequent neointima formation and demonstrate an impaired thrombus formation under high-shear conditions.

Platelet GPVI has been gradually recognized to play a role in ischaemic stroke. Platelet adhesion and activation enhance the infarct growth by promoting an inflammatory response. GPVImediated platelet activation can lead to the release of IL-1α that induces cerebrovascular inflammation. Thus, GPVI may serve as an antithromboinflammation target. Currently, two strategies targeting GPVI have reached advanced stages of development. The first is the antibody Fab 9012, which binds and blocks the collagen/fibrin-binding site of GPVI with high affinity (figure 1). This approach has demonstrable antithrombotic efficacy in preclinical models of thrombosis and seems to maintain haemostasis (table 1). A humanized scFv form of 9012 is being prepared to enter early phase clinical trials. The second anti-GPVI is the humanized Fc fusion protein of the GPVI ectodomain called revacept (figure 1). In animal models, revacept protected against thrombosis, ischaemia-reperfusion injury, and stroke. In phase I clinical trials, revacept inhibited collagen-induced human platelet aggregation. Phase II trials of revacept in patients with carotid artery stenosis, transient ischaemic attack, or stroke are ongoing (table 1). Interestingly, this therapeutic seems to be particularly potent at inhibiting thrombus growth under pathological shear conditions ex vivo, suggesting that its antithrombotic effects might be maintained at sites of atherosclerotic plaque rupture, consistent with the fact that collagens are highly abundant in atherosclerotic plaques. Some other GPVI targeted agents that are under investigation, such as losartan, have been shown to inhibit the binding of GPVI to collagen (table 1; figure 1).

**CONCLUDING REMARKS**

Many FDA approved antiplatelet agents are less efficient in relieving arterial thrombosis in severe stenosis, in part due to that they only target agonist pathways rather than the biomechanical platelet aggregation mechanisms. Hereby, we propose that targeting platelet mechanosensing pathways may represent a novel strategy to prevent thrombotic complications. This new strategy uses high-shear flow as the ‘trigger’ of effect, and therefore should be specific in preventing occlusive thrombosis in stenosed arteries. In parallel, current inhibitors of GPIb and GPIb/IIIa extracellular activity were shown to cause adverse effect of bleeding, because they are unable to discriminate the haemostatic versus thrombotic conditions. From a biomechanical perspective, we highlight that although thrombosis and haemostasis share similarity in most aspects, a key difference is that only thrombosis heavily relies on shear-resistant platelet aggregation for endovascular clot growth. This comparison is supported by an interesting evolutionary perspective: the avian thrombocytes have similar adhesion and signaling behaviours as mammalian platelets, but cannot form shear-resistant aggregates; in consequence, thrombocytes support haemostasis but cannot form occlusive thrombi in vivo. Therefore, inhibitors that weaken GPIb and GPIb/IIIa binding under thrombotic haemodynamic conditions, should selectively prevent shear-resistant platelet aggregates towards artery occlusion. The above new antithrombotic strategies, which are under development or yet to be tested, promise a ‘mechano-medicine’ to solve the long lingering question...
of how to effectively inhibit arterial thrombosis without causing excessive bleeding.

**Correction notice** This article has been corrected since it was first published. Orcid ID for author Lining Arnold Ju has been added.

**Contributors** Both authors wrote the manuscript and made the table. YC drew the figures.

**Funding** This work was supported by grants from Sydney Research Accelerator (SOAR) prize (L.A.J.), The Royal College of Pathologists of Australasia Kanematsu Foundation (L.A.J.) and the Cardiac Society of Australia and New Zealand BAYER Young Investigator Research Grant (L.A.J.). We thank Zaverio Ruggeri, Yilong Wang, Liping Liu, Jing-fai Dong and Yi Qian for helpful discussion. Y.C. is a MERU (Medical-Research-University) Foundation post-doctoral awardee. L.A.J. is an Australian Research Council DECRA fellow (DE190100609) and a National Heart Foundation Future Leader fellow (102532).

**Competing interests** None declared.

**Patient consent for publication** Not required.

**Provenance and peer review** Commissioned; internally peer reviewed.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

**ORCID iDs** Yunfeng Chen http://orcid.org/0000-0001-7618-107X
Lining Arnold Ju http://orcid.org/0000-0002-7591-0864

**REFERENCES**


Bosch X, Marrugat J, Sanchis J. Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromes. The Cochrane database of systematic reviews. 2013:CD002130.


